Live News Categoriesequity

Neurizon Therapeutics Limited (NUZ.AX) News

Follow Neurizon Therapeutics Limited (NUZ.AX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol NUZ.AX Asset equity Sector Markets 90 days 1 Last 0.09 Updated Oct 06, 2026, 01:10 AM UTC Open live news feed Open NUZ.AX chart & news

M Neurizon Therapeutics' potential drug NUZ-001 for ALS gets nod for traditional FDA approval pathway Neurizon Therapeutics shares rose as much as 14.3% to A$0.096 after the U.S. Food and Drug Administration (FDA) affirmed the potential of a traditional approval pathway for its drug NUZ-001, given substantial evidence of EQUITY | Oct 06, 2026, 01:10 AM UTC